Michael B. Atkins, MD

Rapid Readouts: Results of Phase 3 DREAMseq Trial in Advanced Melanoma

February 9th 2022

Michael Atkins, MD, shares data presented at the 2021 American Society of Clinical Oncology Plenary Series regarding results from the phase 3 ECOG-ACRIN EA6134 trial, DREAMseq, evaluating the use of up-front dual immunotherapy in patients with BRAF V600–mutant advanced melanoma.

Dr. Atkins on the FDA Approval of Tivozanib in Relapsed/Refractory Advanced RCC

March 16th 2021

Michael B. Atkins, MD, discusses the FDA approval of tivozanib in relapsed/refractory advanced renal cell carcinoma.

Dr. Atkins on the Efficacy of Dabrafenib/Trametinib in BRAF-Mutated Melanoma

March 1st 2021

Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.

Dr. Atkins on the Benefits of Neoadjuvant Therapy in Melanoma

December 15th 2020

Michael B. Atkins, MD, discusses the benefits of neoadjuvant therapy in melanoma.

Dr. Atkins on the Expanding Role of Immunotherapy in Oncology

October 30th 2020

Michael B. Atkins, MD, discusses the expanding role of immunotherapy in oncology.

Dr. Atkins on the Impact of Georgetown Lombardi Cancer Center Consortium on Sarcoma Treatment

October 26th 2020

Michael B. Atkins, MD, discusses the impact of the Georgetown Lombardi Cancer Center Consortium on the treatment of patients with sarcoma.

Dr. Atkins on the Importance of the Georgetown Lombardi Cancer Center Consortium

October 26th 2020

Michael B. Atkins, MD, discusses the importance of the Georgetown Lombardi Cancer Center Consortium.

Dr. Atkins on Long-Term Outcomes of the CheckMate-204 Trial in Melanoma

October 15th 2019

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses long-term outcomes of the CheckMate-204 trial in melanoma.

Dr. Atkins on CA209-004 Trial Results in Advanced Melanoma

October 3rd 2019

Michael B. Atkins, MD, discusses results from the CA209-004 trial, which was a phase I study analyzing patients with advanced, unresectable melanoma treated with nivolumab plus ipilimumab.

Dr. Atkins on Long-Term Survival Benefit of Nivolumab/Ipilimumab in Advanced Melanoma

August 22nd 2019

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses data from a phase I trial exploring the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma.

Dr. Atkins Discusses the Adjuvant Treatment of Melanoma

December 8th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the adjuvant treatment of melanoma.

Dr. Atkins Discusses Response to Atezolizumab in RCC

August 16th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma.

Dr. Atkins on Sequencing of Immunotherapy Combination Regimens

August 3rd 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).

Dr. Atkins on Excitement With Atezolizumab and Bevacizumab in RCC

July 27th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the excitement surrounding the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).

Dr. Atkins on Results of Atezolizumab Plus Bevacizumab in RCC

June 29th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the results of a trial of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Dr. Atkins Discusses the IMmotion150 Trial in RCC

June 16th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the IMmotion150 trial in renal cell carcinoma.

Dr. Atkins on Adjuvant Ipilimumab in Melanoma

April 7th 2016

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the adjuvant use of ipilimumab (Yervoy) in patients with melanoma.